首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1672815

急性細菌性皮膚和皮膚結構感染疾病市場按藥物類型、感染類型、給藥途徑、分銷管道和地區分類

Acute Bacterial Skin And Skin Structure Infections Market, By Drug Type, By Infection Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年02月14日 | 出版商:

Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球急性細菌性皮膚和皮膚結構感染疾病市場規模估計為 40.734 億美元，預計到 2032 年將達到 61.29 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 6.0%。

報告範圍		報告詳細資訊
基準年	2024	2025 年市場規模	40.734億美元
效能資料	2020-2024	預測期	2025-2032
預測期：2025 年至 2032 年複合年成長率	6.00％	2032 年金額預測	61.29億美元

數字。 2025 年急性細菌性皮膚和皮膚結構感染疾病市場佔有率（%）

急性細菌性皮膚和皮膚結構感染疾病(ABSSSI) 是指影響皮膚和周圍組織和結構的常見細菌感染疾病，包括主要皮膚膿腫、蜂窩性組織炎組織炎以及感染性傷口和潰瘍。引起 ABSSSI 的常見細菌包括金黃色葡萄球菌和化膿性鏈球菌。由於抗生素抗藥性的增加以及肥胖、糖尿病和生活方式改變等風險因素的增加，全球 ABSSSI 發生率正在上升。

市場動態

全球老年人口和糖尿病等合併症的增加增加了 ABSSSI 的風險。根據國際糖尿病聯盟的數據，2020年約有4.63億20-79歲的成年人患有糖尿病，預計到2045年這一數字將上升到7億以上。老年人也更容易受到皮膚和軟組織感染疾病。快速的都市化和生活方式的改變損害了免疫健康，進一步增加了全球 ABSSSI 的疾病負擔。然而，有關臨床測試和藥物核准的嚴格規定可能會阻礙市場的成長。新型抗菌藥物的持續研發和先進創傷護理療法的快速應用為市場提供了豐厚的機會。

研究的主要特點

本報告對全球急性細菌性皮膚和皮膚結構感染疾病市場進行了詳細分析，並提供了預測期（2025-2032 年）的市場規模（百萬美元）和年複合成長率（CAGR%），假設基準年為 2024 年。
它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
全球急性細菌性皮膚和皮膚結構感染疾病市場的主要企業根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行分析。
主要企業包括 Fresenius SE &Co.KGaA、輝瑞公司、Amneal Pharmaceuticals LLC、Intas Pharmaceuticals Ltd.、卡迪拉醫療保健有限公司、Glenmark Pharmaceuticals Ltd.、葛蘭素史克公司、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharmau.、艾伯維公司、Melevas Ltd. s, Inc. 等。
本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球急性細菌性皮膚和皮膚結構感染疾病市場迎合了該行業的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過全球急性細菌性皮膚和皮膚結構感染市場分析中使用的各種策略矩陣來促進他們的決策。

公司簡介
- Fresenius SE &Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck &Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.

第 11 章分析師建議

興衰
一致的機會地圖

第 12 章參考文獻與調查方法

參考
調查方法

簡介目錄

Product Code: CMI1531

Global Acute Bacterial Skin And Skin Structure Infections Market is estimated to be valued at USD 4,073.4 Mn in 2025 and is expected to reach USD 6,129.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 4,073.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.00%	2032 Value Projection:	USD 6,129.0 Mn

Figure. Acute Bacterial Skin And Skin Structure Infections Market Share (%), By Region 2025

Acute Bacterial Skin And Skin Structure Infections Market - IMG1

Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2020, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

By Drug Type:
- Oral & Parenteral Antibiotics
- Oritavancin
- Delafloxacin
- Vancomycin
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
By Route of Administration:
- Oral
- Parenteral
- Topical
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Fresenius SE & Co. KGaA
- Pfizer, Inc.
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Infection Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Manufacturer Revenue
Adoption of Non-invasive Sensor Technologies
Acquisitions and Partnerships Scenario
Product Launches/Approvals
Funding and Investments
PEST Analysis
Porter's Analysis

4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Government Initiatives
COVID-19 Impact on the Market

5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Oral & Parenteral Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Oritavancin
Delafloxacin
Vancomycin
Others
Topical Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Hydrogen Peroxide
Fusidic Acid
Mupirocin
Retapamulin

6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospital Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Community Acquired ABSSSI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Topical
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2020 - 2032, (USD Mn)

Overview
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2020 - 2032, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- Fresenius SE & Co. KGaA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Amneal Pharmaceuticals LLC
- Intas Pharmaceuticals Ltd.
- Cadila Healthcare Ltd.
- Glenmark Pharmaceuticals Ltd
- GSK plc
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- AbbVie, Inc.
- Melinta Therapeutics, Inc.
- Accord Healthcare Ltd.
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.